Tumor and stromal cell targeting with Nintedanib and Alpelisib overcomes intrinsic bladder cancer resistance. Marques M, Corral S, Sanchez-Diaz M, Del Pozo N, et al. Mol Cancer Ther 2023 Feb 20:MCT-21-0667. doi: 10.1158/1535-7163.MCT-21-0667.

Read + Share

Amedeo Smart

Independent Medical Education

Marques M, Corral S, Sanchez-Diaz M, Del Pozo N, et al. Tumor and stromal cell targeting with Nintedanib and Alpelisib overcomes intrinsic bladder cancer resistance. Mol Cancer Ther 2023 Feb 20:MCT-21-0667. doi: 10.1158/1535-7163.MCT-21-0667.
PMID: 36805958